Portal de Periódicos da CAPES

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

2023; Lippincott Williams & Wilkins; Volume: 41; Issue: 15 Linguagem: Inglês

10.1200/jco.22.02221

1527-7755

Renata Ferrarotto, Luana Guimarães de Sousa, Lei Feng, Frank E. Mott, George R. Blumenschein, Mehmet Altan, Diana Bell, Flavia Bonini, Kaiyi Li, Mario L. Marques‐Piubelli, Eduardo A. Dal Lago, Jason M. Johnson, Yoshitsugu Mitani, Myrna C. B. Godoy, Anna Lee, Michael E. Kupferman, Ehab Y. Hanna, Bonnie S. Glisson, Yasir Y. Elamin, Adel K. El‐Naggar,

Sarcoma Diagnosis and Treatment

We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).